Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-12-17-Speech-3-107"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-12-17"^^xsd:date2
dcterms:Is Part Of	lp_eu:Vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20031217.4.3-107"2
lpv:hasSubsequent	lp_eu:2003-12-17-Speech-3-1082
lpv:speaker	lp:Martine Roure2
lpv:spokenAs	member_of_the_bureau; PES (2002-01-17--2004-07-19)3 substitute; Committee on Culture, Youth, Education, the Media and Sport (2002-01-17--2004-07-19)3 member; Delegation for relations with the People's Republic of China (2002-02-07--2004-07-19)3 unknown; Parti socialiste (1999-07-20--2004-07-19)3 member; Committee on Citizens' Freedoms and Rights, Justice and Home Affairs (2002-01-17--2004-07-19)3
lpv:translated text	"We have just expressed our opinion on the revision of pharmaceutical legislation. The modified directive will allow a greater degree of harmonisation between the Member States when it comes to the rules governing medicines. It may increase the effectiveness with which the centralised and decentralised procedures operate. We want the Member States to ensure, however, that preference is given to homeopathic medicines manufactured and marketed in the Community. We have voted in favour of the amendments that could resolve a number of problems caused by the legal vacuum in which certain homeopathic medicines still exist. Not only do these medicines, used by more than a hundred million Europeans, not have side effects, but they also enable the health services to make savings. We are definitely keen to preserve those homeopathic medicines that meet the demand from our countries’ citizens. We have also come out in favour of developing Europe’s generic pharmaceutical industry, for, if we want to preserve our social protection, we have to make savings, and generic medicines help us do that."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph